• Gene fusion; HGNC; HGNC:11340; SS18 + HGNC; HGNC:11336; SSX2; Name(s)=SS18-SSX2 (PubMed=14744540; DepMap=ACH-001275).
  
• Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap=ACH-001275).
  

PubMed=14744540; DOI=10.1016/j.canlet.2003.09.031
Kawai A., Naito N., Yoshida A., Morimoto Y., Ouchida M., Shimizu K., Beppu Y.
Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1.
Cancer Lett. 204:105-113(2004)

PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27353471; DOI=10.1111/gtc.12387
Yamasaki H., Miyamoto M., Yamamoto Y., Kondo T., Watanabe T., Ohta T.
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Genes Cells 21:852-860(2016)